1. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans 
Byron Cryer, Mark Feldman 
Gastroenterology 
Volume 117, Issue 1, Pages (July 1999)
DOI: /S (99)
Copyright © 1999 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Mean (±SEM) serum TXB2 concentrations after 0 (baseline), 1.5, and 3 months of aspirin treatment at 10 (2; n = 8), 81 (■; n = 11), or 325 (●; n = 10) mg/day. At 3 months, n = 7 in the 10-mg/day aspirin group and n = 9 in the 325-mg/day aspirin group. *P ≤ 0.01 vs. 0 months by the Wilcoxon signed-rank test; ΦP ≤ vs. aspirin at 10 mg/day by the Kruskal–Wallis test.
Gastroenterology  , 17-25DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Effects of aspirin treatment at 10 (2; n = 8), 81 (■; n = 11), or 325 (●; n = 10) mg/day on mucosal PG concentrations in the stomach (gastric body and antrum combined), duodenum (bulb and postbulbar duodenum combined), and rectum expressed as a percentage (±SEM) of the baseline value. Dashed line represents baseline mucosal PG concentrations before exposure to aspirin (see text). Data at 1.5 and 3 months and data in the various mucosal regions have been averaged. In the rectum, n = 7 for each aspirin-dosage group, and no biopsy specimens were taken at 1.5 months. *P < 0.05 vs. baseline by the Wilcoxon signed-rank test.
Gastroenterology  , 17-25DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

4. Fig. 3
Effects of aspirin treatment at 10 (2; n = 8), 81 (■; n = 11), or 325 (●; n = 10) mg/day on endoscopic injury scores in the stomach (gastric body and antrum combined), duodenum (bulb and postbulbar duodenum combined), and rectum, expressed as a change (±SEM) from the baseline value. Data from 1.5 and 3 months were averaged in the various regions. In the rectum, n = 7 for each aspirin-dosage group, and no biopsy specimens were taken at 1.5 months. *P ≤ 0.05 vs. baseline by the Wilcoxon signed-rank test.
Gastroenterology  , 17-25DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions